New data released by BrainStorm Cell Therapeutics has revealed promising results for their ALS treatment, NurOwn. The Phase 3 trial showcased a significant reduction in the neurodegeneration biomarker, NfL, among participants who received NurOwn compared to those who were given a placebo. The decision to analyze biomarker data was influenced by recent FDA approvals for ALS drugs and the correlat..
Experts suggest that expanding eligibility for amyotrophic lateral sclerosis (ALS) trials could benefit patients and drug development. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which is an understatement according to investigators. Expanding inclusion criteria would allow more patients to access experimental treatments and help drug develope..
Expanding eligibility criteria for early-phase ALS clinical trials could benefit both patients and therapeutic progress, according to experts. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which has ethical and drug development implications. Angela Genge, chief medical officer at QurAlis, believes that expanding eligibility is necessary to allow..
